Publicacions en col·laboració amb investigadors/es de Hospital de la Santa Creu i Sant Pau (60)

2024

  1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  2. Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing

    Clinical and Translational Oncology

  3. Profilaxis de la enfermedad tromboembólica venosa en pacientes hospitalizados por patología médica desde los servicios de urgencias españoles: estudio PROTESU II

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 36, Núm. 4, pp. 271-280

2023

  1. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning

    Thrombosis Research, Vol. 228, pp. 181-188

  2. Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

    Haematologica, Vol. 108, Núm. 10, pp. 2652-2663

  3. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

    Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783

  3. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

  4. Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 2, pp. 295-299

  5. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group

    Blood cancer journal, Vol. 12, Núm. 4, pp. 76

2021

  1. Characteristics of isolated superficial vein thrombosis and diagnostic-therapeutic management in spanish hospital emergency departments:The altamira study

    Emergencias, Vol. 33, Núm. 6, pp. 433-440

2018

  1. Cancer-associated thrombosis: Beyond clinical practice guidelines-A multidisciplinary (SEMI-SEOM-SETH) expert consensus

    TH Open, Vol. 2, Núm. 4, pp. e373-e386

2017

  1. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA/GEM trial

    Leukemia, Vol. 31, Núm. 9, pp. 1922-1927

  2. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: The DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsa

    Emergencias, Vol. 29, Núm. 1, pp. 18-26

  3. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

    Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009

2016

  1. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma

    British Journal of Haematology, Vol. 175, Núm. 3, pp. 448-456

2015

  1. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

    British Journal of Haematology, Vol. 170, Núm. 6, pp. 804-813

  2. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study

    Haematologica, Vol. 100, Núm. 10, pp. 1294-1300

  3. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

    Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69